PhagoMed Biopharma GmbH successfully completed another financing round.

Investors provided further €1.5 million in equity investments to support phage therapy to tackle the antibiotics crisis.

PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. 

Already in 2018 PhagoMed successfully raised more than €4 million in public grants and private investments and set-up its research programs. The company has now announced further investments totaling €1.5 million.

The additional funding will be used to accelerate three in-house development programs.

Read more.